Transcription Factors Involved in Prostate Gland Adaptation to Androgen Deprivation

被引:19
|
作者
Rosa-Ribeiro, Rafaela [1 ]
Nishan, Umar [1 ]
Vidal, Ramon Oliveira [2 ]
Barbosa, Guilherme Oliveira [1 ]
Reis, Leonardo Oliveira [3 ]
Cesar, Carlos Lenz [4 ,5 ]
Carvalho, Hernandes F. [1 ,5 ]
机构
[1] Univ Estadual Campinas, Dept Struct & Funct Biol, Sao Paulo, Brazil
[2] Natl Ctr Res Energy & Mat, Lab Bioinformat, Sao Paulo, Brazil
[3] Univ Estadual Campinas, Div Urol, Sao Paulo, Brazil
[4] Univ Estadual Campinas, Dept Quantum Phys, Sao Paulo, Brazil
[5] Univ Estadual Campinas, Natl Inst Photon Appl Cell Biol INFABiC, Sao Paulo, Brazil
来源
PLOS ONE | 2014年 / 9卷 / 06期
基金
巴西圣保罗研究基金会;
关键词
VENTRAL PROSTATE; B-MYB; PROGRAMMED DEATH; CELL-CYCLE; KAPPA-B; RECEPTOR; CANCER; EXPRESSION; APOPTOSIS; PROLIFERATION;
D O I
10.1371/journal.pone.0097080
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Androgens regulate prostate physiology, and exert their effects through the androgen receptor. We hypothesized that androgen deprivation needs additional transcription factors to orchestrate the changes taking place in the gland after castration and for the adaptation of the epithelial cells to the androgen-deprived environment, ultimately contributing to the origin of castration-resistant prostate cancer. This study was undertaken to identify transcription factors that regulate gene expression after androgen deprivation by castration (Cas). For the sake of comparison, we extended the analysis to the effects of administration of a high dose of 17 beta-estradiol (E2) and a combination of both (Cas+ E2). We approached this by (i) identifying gene expression profiles and enrichment terms, and by searching for transcription factors in the derived regulatory pathways; and (ii) by determining the density of putative transcription factor binding sites in the proximal promoter of the 10 most up- or down-regulated genes in each experimental group in comparison to the controls Gapdh and Tbp7. Filtering and validation confirmed the expression and localized EVI1 (Mecom), NFY, ELK1, GATA2, MYBL1, MYBL2, and NFkB family members (NFkB1, NFkB2, REL, RELA and RELB) in the epithelial and/or stromal cells. These transcription factors represent major regulators of epithelial cell survival and immaturity as well as an adaptation of the gland as an immune barrier in the absence of functional stimulation by androgens. Elk1 was expressed in smooth muscle cells and was up-regulated after day 4. Evi1 and Nfy genes are expressed in both epithelium and stroma, but were apparently not affected by androgen deprivation.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] ABCC3 expression is up-regulated in prostate gland after androgen deprivation.
    Rosa-Ribeiro, R.
    Carvalho, H. F.
    MOLECULAR BIOLOGY OF THE CELL, 2014, 25
  • [32] Does Neoadjuvant Androgen Deprivation Therapy Before Primary Whole Gland Cryoablation of the Prostate Affect the Outcome?
    Grossgold, Erik
    Given, Robert
    Ruckle, Herbert
    Jones, J. Stephen
    UROLOGY, 2014, 83 (02) : 379 - 384
  • [33] Androgen deprivation therapy for precancerous lesions of the prostate
    Hull, David
    Bostwick, David G.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 22 (02) : 285 - 291
  • [34] Intermittent androgen deprivation in advanced prostate cancer
    T. M. de Reijke
    Urological Research, 1997, 25 : S63 - S66
  • [35] miRNAs and androgen deprivation therapy for prostate cancer
    Konoshenko, Maria Yu
    Bryzgunova, Olga E.
    Laktionov, Pavel P.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (02):
  • [36] Lack of prostate cancer radiosensitization by androgen deprivation
    Pollack, A
    Salem, N
    Ashoori, F
    Hachem, P
    Sangha, M
    Von Eschenbach, AC
    Meistrich, ML
    JOURNAL OF UROLOGY, 2002, 168 (01): : 378 - 378
  • [37] Androgen deprivation and immunotherapy for the treatment of prostate cancer
    Gamat, Melissa
    McNeel, Douglas G.
    ENDOCRINE-RELATED CANCER, 2017, 24 (12) : T297 - T310
  • [38] Androgen deprivation as a strategy for prostate cancer chemoprevention
    Aquilina, JW
    Lipsky, JJ
    Bostwick, DG
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (10): : 689 - 696
  • [39] Trends in the use of androgen deprivation in prostate cancer
    Salminen, EK
    Wickström, JE
    Vahlberg, T
    Duchesne, GM
    ACTA ONCOLOGICA, 2004, 43 (04) : 382 - 387
  • [40] HISTORY OF ANDROGEN DEPRIVATION APPROACHES FOR PROSTATE CANCER
    Phillips, Jason
    Siomos, Vassilis
    Westfall, Nicholas
    Kenny, McCabe
    Spendlove, Joshua
    Pshak, Thomas
    Larke, Robert
    Rove, Kyle
    Crawford, E. David
    JOURNAL OF UROLOGY, 2014, 191 (04): : E631 - E632